Iterum Therapeutics Provides Business Update: Resubmission of NDA is On Track for First Half of Q2 24
Iterum Therapeutics, a renowned pharmaceutical company specializing in the development and commercialization of innovative anti-infectives, recently released a press statement providing a comprehensive business update. Key among the updates is the resubmission of their New Drug Application (NDA), which remains firmly on track for the first half of the second quarter of 2024.
The company has been diligently working towards resubmitting their NDA following the receipt of a Complete Response Letter (CRL) from the Food and Drug Administration (FDA) for their lead product candidate, sulopenem, in April 2021. The CRL cited concerns regarding the adequacy of the prospective drug’s safety profile and its potential impact on hepatic safety.
Iterum Therapeutics swiftly responded to the FDA’s concerns by initiating several studies and trials to further analyze the safety profile of sulopenem. These studies aimed to address the concerns identified in the CRL and provide the necessary data for the resubmission of the NDA.
Since the receipt of the CRL, Iterum Therapeutics has undertaken multiple efforts to optimize sulopenem’s characterization, evaluate drug-drug interactions, and assess hepatic safety. In accordance with the FDA’s recommendations and guidance, the company conducted in vitro studies to investigate hepatocyte apoptosis, examined reactive metabolite formation, and evaluated bile salt export pump inhibition.
Moreover, Iterum Therapeutics diligently worked on a comprehensive program to better understand the safety profile of sulopenem. This program included clinical studies involving subjects with and without hepatic impairment, simulations of liver cirrhosis population experiences, and mechanistic evaluation in test systems. By conducting these in-depth studies, Iterum Therapeutics aimed to provide robust scientific evidence to address the FDA’s concerns and ensure the safety of sulopenem for patients who may require this therapy.
Based on their findings, Iterum Therapeutics is confident that the resubmission of the NDA is a significant step forward in making sulopenem available to physicians and patients in need. They are optimistic that the comprehensive data obtained through their rigorous studies will demonstrate the drug’s safety and efficacy, paving the way for its potential approval.
The decision to resubmit the NDA in the first half of the second quarter of 2024 is a testament to Iterum Therapeutics’ commitment to addressing the FDA’s concerns promptly and thoroughly. The company’s dedication to patient safety and its determination to provide physicians with an effective tool in combating infections remain at the forefront of their actions.
Iterum Therapeutics is excited about the potential of sulopenem and its impact on public health as it seeks to address the growing threat of multi-drug resistant pathogens. Despite the challenges faced, the company remains resilient and optimistic, focused on delivering innovative solutions to patients and healthcare professionals.
In conclusion, Iterum Therapeutics is on track to resubmit their NDA for sulopenem in the first half of the second quarter of 2024. The company’s commitment to addressing the FDA’s safety concerns through rigorous studies and extensive evaluation demonstrates their dedication to patient well-being. Iterum Therapeutics believes that sulopenem has the potential to be a game-changer in the fight against multi-drug resistant pathogens, and they are steadfast in their pursuit to make this innovative therapy available to patients and physicians alike.
Comments